PPT-Prostate and Breast Cancer

Possible Ways to Reduce Your Chances Dr Frank F Mallory Full Professor and Past Chair Department of Biology Laurentian University Sudbury Ontario CANADA If You Google Age and Testosterone. Norm D. Smith, M.D.. Associate Professor. Co-Director. Urologic Oncology. University of Chicago. United States Preventive Services Task Force (USPSTF). USPSTF Warns Against Blood Test For Prostate Cancer. . Julian Mander . RPH Urology. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a . May 19, 2017. Hereditary Cancer Syndromes. Recognition. , . Testing and . Management. . Disclosures. Nothing to disclose. Objectives. Recognize . patterns of hereditary cancer syndromes and identify appropriate patients for referral . Susan Hingle, MD, FACP. Professor of Medicine. Division of General Internal Medicine. Interim Chair. SIU School of Medicine. Session Objectives. Identify the cancers in which aspirin therapy may play a role in prevention.. Screening Tests and . Self-exams. Screening tests:. Colon . Breast. Cervical . Prostate . Self-exams:. Testicular. Skin . Why Screening Tests?. The treatment of cancer is most successful when the cancer is detected as early as possible, often before symptoms occur.. The second most common cancer diagnosed in men. The incidence increase with age very rare before age of 40, more in western countries particularly Scandinavian countries (low light exposure), and black men are at greatest risk. If you decide not to get screened, you can always change your mind later. If you decide to get screened, it does not mean you have to go to the next step. You should discuss each step with your docto Azeez Farooki, MD. Attending Physician, Clinical Member. Memorial Sloan Kettering Cancer Center. New York, NY. Objectives. Elucidate the problem of aromatase inhibitor induced bone loss and increased risk of fractures in breast cancer. Clinical implementation of testing and PARP. i. monotherapy, and the patient journey for prostate cancer patients. Dr Neal Shore. , . MD, FACS. Carolina Urologic Research Center and Chief Medical Officer for Genesis Care, USA. Latest developments. . Prof.. . Neeraj Agarwal, MD. Director, Genitourinary Oncology Program, . Huntsman Cancer Institute, University of Utah, USA. MARCH 2022. PARPi. , poly-ADP ribose polymerase inhibitors. Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. Daryl P. Lofaso, P. h. .D., . M.Ed. , RRT. Urethral Catheterization. Indications. Long Term. Refractory bladder outlet obstruction. Neurogenic bladder with urinary retention. Complications of incontinence.